New Plasmid
Manufacturing Facilitiy

A new state-of-the-art facility dedicated to plasmid manufacturing

Plasmids

Anemocyte is the leading Italian producer of gene therapy plasmids and is one of the first of its kind in Europe. Having recently built a brand new Plasmid Manufacturing Unit – which is dedicated to producing plasmids for viral vectors – Anemocyte is equipped with state-of-the-art laboratories and facilities, having tripled its production output since 2018.

 

The company’s improved production capacity makes it the perfect partner for researching, developing and producing R&D, High Quality and GMP plasmids, from pre-clinical and clinical phases to commercial production.

“In a market where production wait times are extremely long, Anemocyte is able to respond to biopharma company requests quickly and with the highest quality standards,”

 

Stefano Baila, Director of Operations and Business Development at Anemocyte.

 

“And it’s all because Anemocyte is a dynamic market player equipped with cutting-edge technologies and over ten years of expertise producing recombinant proteins; experience that it now exploits to produce plasmids – our core business. Pioneering production plants, scrupulous quality control systems, single-use technologies, cross-cutting skills and a flexible production system make us a dynamic enterprise able to intercept market needs and offer punctual, effective and qualitatively competitive results.”

WHERE WE ARE

Anemocyte Headquarters

Plasmid Manufacturing  – 300m2 of cleanrooms, the plasmid unit of Anemocyte address manufacturing needs Plasmids for Viral Vectors from R&D to GMP.

Anemocyte vision

21-24 January 2020

Phacilitate Leaders World 2020 – Miami,

“Phacilitate Leaders World is an unmissable event for industry professionals”,

states Marco Ferrari, CEO of Anemocyte.

“It’s an opportunity to take stock of the cell and gene therapies sector, which is in constant evolution. It no longer suffices to remain in step with market demands, we need to anticipate them and offer innovative, effective solutions and strategies.”

Anemocyte brings Italian excellence in the Cell and Gene Therapy sector to Phacilitate Leaders World 2020 in Miami

At the cutting edge of Cell and Gene therapy and a centre of excellence for the production of plasmids and non-viral solutions for genetic modifications, Anemocyte will be a key player at the leading sector event thanks to its expertise, dynamism and industrial cell and plasmid manufacturing facilities

Phacilitate Leaders World – a leading event for companies, professionals and investors working in the Cell and Gene Therapy sector – returns to Miami from 21 to 24 January 2020. Anemocyte is an innovative Italian company working in the field of cell and gene therapies, with special focus on plasmid production and non-viral gene modification approaches. The company attends this important event as a key player thanks to its expertise in cutting-edge technologies, including MaxCyte electroporation technology for non-viral genetic modification, which is used to develop and produce medicinal products for CGTs (Cell and Gene Therapies). The company also showcases a series of additional projects, including FLYn’Ice, which yet further establish Anemocyte’s position as the first ever Biotech Manufacturing Organization (BMO) operating in the Life Science sector…

[read more]

About us

Anemocyte news

PRESS AREA

In this press release page you can find a selection of the main articles about Anemocyte
published by newspapers and magazines, both online and on paper.

CONTACT US

Let’s make real change happen together.

Anemocyte S.r.l.

 

Single Shareholder Private Limited-Liability Company

Via R. Lepetit, 34 | 21040 Gerenzano (VA) Italy
Ph: +39 02 99372311 | Fax: +39 02 99372313

VAT number: 12914940155
Share capital € 530.000,00 fully paid
R.E.A. 276961

Anemocyte is a proud member of

Anemocyte S.r.l.
Single Shareholder Private Limited-Liability Company

Via R. Lepetit, 34 | 21040 Gerenzano (VA) Italy
Ph: +39 02 96474804 | Fax: +39 02 96474800

VAT number: 12914940155
Share capital € 530.000,00 fully paid
R.E.A. 276961

  • This field is for validation purposes and should be left unchanged.